Trial ID 20298 | Maryland Oncology Hematology Trial ID 20298 – Maryland Oncology Hematology

Trial ID 20298

Trial Information - Phase II

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer

Protocol ID: VS-6766-201 GOG 3052

Sponsor: GOG Foundation/Verastem, Inc

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Ovarian

Investigator

Tweed MD, Carol

Status

OPEN TO ENROLLMENT

Sponsor

GOG Foundation/Verastem, Inc

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology